stockportfolio.pro
Stocks / EWTX vs HAE
EWTX vs HAE
Edgewise Therapeutics, Inc. and Haemonetics Corporation side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Edgewise Therapeutics, Inc. (EWTX) | Haemonetics Corporation (HAE) | |
|---|---|---|
| Market cap | $3.7B | $3.6B |
| Revenue (latest FY) | $0 | $1.33B |
| Net income (latest FY) | $-167.79M | $97.31M |
| Revenue growth (5y CAGR) | — | 8.9% |
| Net margin | — | 7.3% |
| Return on equity | -32.1% | 12.2% |
| P/E ratio | — | 38.4 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 9 |
| Positive free cash flow | No | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open EWTX — free Open HAE — freeFrequently asked questions
Which is bigger, EWTX or HAE?
Edgewise Therapeutics, Inc. is larger by market capitalization — $3.7B versus $3.6B.
Which grows faster, EWTX or HAE?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.